VpreB1 Inhibitors
Chemical inhibitors of VpreB1 can exert their effects through a variety of molecular mechanisms, each targeting different aspects of the signaling pathways crucial for B cell development and maturation. Imatinib targets the tyrosine kinase activity of the B cell receptor, to which VpreB1 is a contributor, by forming a complex with the surrogate light chain part of the pre-BCR on early B cells. Dasatinib, a Src family kinase inhibitor, interferes with downstream signaling of the pre-B cell receptor complex, impacting the functional activities of VpreB1 through the inhibition of Lyn and other Src family kinases. Similarly, Idelalisib's selective inhibition of phosphoinositide 3-kinase delta (PI3Kδ) impairs the signaling pathways involving VpreB1, thus affecting its role in B cell activation.
In addition, Ibrutinib and Acalabrutinib, as Bruton's tyrosine kinase (BTK) inhibitors, disrupt the B cell receptor signaling pathway which involves VpreB1. Zanubrutinib, another selective BTK inhibitor, similarly impedes the signaling cascade that VpreB1 is a part of, leading to functional inhibition. Fostamatinib inhibits spleen tyrosine kinase (Syk), another critical kinase in B cell receptor signaling, thus disrupting the signaling cascade involving VpreB1. Duvelisib, which inhibits both PI3Kδ and PI3Kγ isoforms, also disrupts the signaling processes critical for the functional role of VpreB1 in B cell development. Additionally, Ruxolitinib, a Janus kinase (JAK) inhibitor, interferes with cytokine signaling pathways in B cell development where VpreB1 plays a part. Venetoclax, a Bcl-2 inhibitor, causes apoptosis in B cells, affecting the population of cells where VpreB1 exerts its function. Lastly, Copanlisib, as a pan-class I PI3K inhibitor with strong activity against PI3Kα and PI3Kδ, disrupts the signaling pathways that involve VpreB1, leading to its functional inhibition in the context of B cell activation and development.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $25.00 $117.00 $209.00 | 27 | |
Imatinib inhibits the tyrosine kinase activity of the B cell receptor (BCR), and since VpreB1 forms a complex with the surrogate light chain part of the pre-BCR on early B cells, this inhibition could reduce the signal transduction required for B cell development, leading to a functional inhibition of VpreB1's role in early B cell maturation. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib, a Src family kinase inhibitor, can interfere with the downstream signaling of the pre-B cell receptor complex, which includes VpreB1. By inhibiting Lyn and other Src family kinases, Dasatinib can suppress the signaling cascade necessary for the functional activity of VpreB1 in B cell development. | ||||||
CAL-101 | 870281-82-6 | sc-364453 | 10 mg | $189.00 | 4 | |
Idelalisib selectively inhibits phosphoinositide 3-kinase delta (PI3Kδ), which plays a crucial role in the activation of B cells. VpreB1 is part of the signaling complex in B cells, and thus the inhibition of PI3Kδ can impair the signaling pathway involving VpreB1, leading to its functional inhibition. | ||||||
Ibrutinib | 936563-96-1 | sc-483194 | 10 mg | $153.00 | 5 | |
Ibrutinib is a Bruton's tyrosine kinase (BTK) inhibitor, which is essential for B cell receptor signaling. VpreB1 is associated with the pre-BCR complex; thus, inhibiting BTK disrupts the signaling involving VpreB1, functionally inhibiting its role in B cell maturation and function. | ||||||
IPI 145 | 1201438-56-3 | sc-488318 | 5 mg | $311.00 | ||
Duvelisib inhibits both PI3Kδ and PI3Kγ isoforms. Given that VpreB1 is involved in the signaling pathways of B cells, the inhibition of PI3Kδ and PI3Kγ would disrupt the signaling processes where VpreB1 is critical, leading to a functional inhibition of its role in B cell development. | ||||||
R788 | 901119-35-5 | sc-364597 sc-364597A | 2 mg 50 mg | $405.00 $4000.00 | 2 | |
R788 inhibits spleen tyrosine kinase (Syk), which is a key player in B cell receptor signaling. By blocking Syk, the signaling cascade involving VpreB1 is disrupted, which would result in the functional inhibition of VpreB1's role in B cell receptor signaling. | ||||||
Acalabrutinib | 1420477-60-6 | sc-507392 | 250 mg | $255.00 | ||
Acalabrutinib is a more selective BTK inhibitor than Ibrutinib. It impairs the B cell receptor signaling pathway involving VpreB1, leading to functional inhibition of VpreB1's role in B cell development and activation. | ||||||
Zanubrutinib | 1691249-45-2 | sc-507434 | 5 mg | $360.00 | ||
Zanubrutinib is another selective BTK inhibitor. By inhibiting BTK, it disrupts the signaling cascade that includes VpreB1, thereby functionally inhibiting VpreB1's role in the B cell receptor complex and B cell function. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $246.00 $490.00 $536.00 | 16 | |
Ruxolitinib is a Janus kinase (JAK) inhibitor that would interfere with cytokine signaling involved in B cell development. As VpreB1 is part of the early B cell signaling complex, the inhibition of JAK can lead to a functional inhibition of VpreB1's role in these cells. | ||||||
ABT-199 | 1257044-40-8 | sc-472284 sc-472284A sc-472284B sc-472284C sc-472284D | 1 mg 5 mg 10 mg 100 mg 3 g | $116.00 $330.00 $510.00 $816.00 $1632.00 | 10 | |
ABT-199 is a Bcl-2 inhibitor, promoting apoptosis in B cells. Since VpreB1 is involved in early B cell development, promoting apoptosis in these cells could functionally inhibit VpreB1 by reducing the number of B cells in which it could act. | ||||||